To include your compound in the COVID-19 Resource Center, submit it here.

Network profiling

Pfizer picks Nodality cell profiling platform to develop lupus compounds

Pfizer Inc. believes new partner Nodality Inc.'s Single Cell Network Profiling technology will provide early insight into a compound's clinical profile, which could help reduce attrition rates, accelerate development and improve patient selection.

The SCNP technology allows functional analysis of a candidate compound's effect on an intracellular network of targets in a single screen.

Under this month's deal, Nodality will use

Read the full 594 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers